Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 11/20 | 0.52 |
| ▸ | ACVR1B | P36896 | 2/20 | 0.51 |
| ▸ | ACVRL1 | P37023 | 2/20 | 0.51 |
| ▸ | ACP1 | P24666 | 7/20 | 0.49 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | FLT1 | P17948 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16587993 | 0.87 | TGFBR1 (0.50) | TGFBR1ACVR1BACVRL1ACP1CYP3A4 | |
| SCHEMBL12090417 | 0.85 | TGFBR1 (0.66) | TGFBR1ACVR1BACVRL1CYP3A4 | |
| SCHEMBL12090540 | 0.85 | ACP1 (0.50) | TGFBR1ACVR1BACVRL1ACP1CYP3A4 | |
| SCHEMBL12090599 | 0.84 | ACP1 (0.52) | TGFBR1ACP1CYP3A4 | |
| SCHEMBL12090458 | 0.83 | ACP1 (0.51) | TGFBR1ACVR1BACVRL1ACP1CYP3A4 | |
| SCHEMBL12090572 | 0.82 | ACP1 (0.50) | TGFBR1ACVR1BACVRL1ACP1CYP3A4 | |
| SCHEMBL12090715 | 0.82 | ACP1 (0.47) | TGFBR1ACVR1BACVRL1ACP1CYP3A4 | |
| SCHEMBL1818846 | 0.82 | TGFBR1 (0.50) | TGFBR1ACP1EGFRFLT1 | |
| SCHEMBL12090564 | 0.82 | ACP1 (0.46) | TGFBR1ACVR1BACVRL1ACP1CYP3A4 | |
| SCHEMBL12090701 | 0.81 | TGFBR1 (0.46) | TGFBR1ACVR1BACVRL1ACP1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8987301-B2 | Heteroarylaminoquinolines as TGF-beta receptor kinase inhibitors | MERCK PATENT GMBH (DE) | 2015-03-24 | — | — | US | disclosed |
| US-8987301-B2 | Heteroarylaminoquinolines as TGF-beta receptor kinase inhibitors | MERCK PATENT GMBH (DE) | 2015-03-24 | — | — | US | disclosed |
| US-8987301-B2 | Heteroarylaminoquinolines as TGF-beta receptor kinase inhibitors | MERCK PATENT GMBH (DE) | 2015-03-24 | — | — | US | disclosed |
| EP-2496234-A1 | HETEROARYLAMINOQUINOLINES AS TGF-BETA RECEPTOR KINASE INHIBITORS | Merck Patent GmbH (DE) | 2012-09-12 | — | — | EP | disclosed |
| US-20120225875-A1 | HETEROARYLAMINOQUINOLINES AS TGF-BETA RECEPTOR KINASE INHIBITORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-09-06 | — | — | US | disclosed |
| US-20120225875-A1 | HETEROARYLAMINOQUINOLINES AS TGF-BETA RECEPTOR KINASE INHIBITORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-09-06 | — | — | US | disclosed |
| US-20120225875-A1 | HETEROARYLAMINOQUINOLINES AS TGF-BETA RECEPTOR KINASE INHIBITORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-09-06 | — | — | US | disclosed |
| WO-2011054433-A1 | HETEROARYLAMINOQUINOLINES AS TGF-BETA RECEPTOR KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2011-05-12 | — | — | WO | disclosed |
| WO-2011054433-A1 | HETEROARYLAMINOQUINOLINES AS TGF-BETA RECEPTOR KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2011-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120225875-A1 | HETEROARYLAMINOQUINOLINES AS TGF-BETA RECEPTOR KINASE INHIBITORS | TGFBR1, TGFBR2, TGFB1 | TGFBR1 1/4885ACVR1B 14/4885ACVRL1 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.